Tags |
|
|
Links |
|
|
Digg it UP - Marketing Authorisation - Medicinal Products
It may be possible that the person gets confused that how faxes get involved with payday loans. Before we move further, let’s know what payday loans are? Payday loan is the product of short term market. These are especially designed for the immediate needs of people. In no fax payday loan, as such no faxes are involved; rather it is an extension of the payday loan. It is regarded as the value added
In seeking marketing authorisation for Product C, the generic companies relied on data submitted in relation to Product A and Product B.
If I had to pick one thing that has made my internet business successful I would have to say it is article submission.Article directories have been all the rage lately, notice the 400 or so new directories to pop up in recent months?Good make note of these...I do not want you to submit to many of these fly by night directories since they likely will never send you any traffic.<
The claimant had marketing authorisations for three medicinal products used in the treatment of osteoporosis and three generic companies sought marketing authorisation for Product C.
Product A - was authorised by the European Community in 1993;
Product B - was authorised in 2000
Product C - was a generic product based on Product B (a copy of Product B).
When a company applies for marketing authorisation for a product, it is a requirement under the European Parliament and Council Directive (EC) 2001/83 (the "Directive"), to supply a full set of data in order to show the safety and efficacy of the product.
There are instances under the Directive when an applicant can simply rely on data submitted in respect of a previously authorised product. For instance, the applicant could refer to data already submitted in respect of a product with marketing authorisation, where the applicant is seeking authorisation for a product 'essentially similar' to a product holding a marketing authorisation for ten years (as per the United Kingdom and pursuant to art 10(i)(a)(iii) of the Directive).
In seeking marketing authorisation for Product C, the generic companies relied on data submitted in relation to Product A and Product B. H
It's a well-known fact that it costs many times more to acquire a new customer than to keep doing business with your existing ones. For this reason, the best way to become profitable is to have loyal customers who keep coming back again and again. It's all about relationship building. So what can you do?Customers Aren't as Loyal as They Used to Be.It used to be that customers would fi
Product A - was authorised by the European Community in 1993;
Product B - was authorised in 2000
Product C - was a generic product based on Product B (a copy of Product B).
When a company applies for marketing authorisation for a product, it is a requirement under the European Parliament and Council Directive (EC) 2001/83 (the "Directive"), to supply a full set of data in order to show the safety and efficacy of the product.
There are instances under the Directive when an applicant can simply rely on data submitted in respect of a previously authorised product. For instance, the applicant could refer to data already submitted in respect of a product with marketing authorisation, where the applicant is seeking authorisation for a product 'essentially similar' to a product holding a marketing authorisation for ten years (as per the United Kingdom and pursuant to art 10(i)(a)(iii) of the Directive).
In seeking marketing authorisation for Product C, the generic companies relied on data submitted in relation to Product A and Product B.
If you could truly learn a skill that could pay you for the rest of your life, how much would that be worth to you?Well the skill is copywriting and it's the most important thing any internet marketer could ever learn. The art of copywriting is really just selling with written words. It's the simple art of persuasion.You're using your copywriting skills when you try to get someone to
When a company applies for marketing authorisation for a product, it is a requirement under the European Parliament and Council Directive (EC) 2001/83 (the "Directive"), to supply a full set of data in order to show the safety and efficacy of the product.
There are instances under the Directive when an applicant can simply rely on data submitted in respect of a previously authorised product. For instance, the applicant could refer to data already submitted in respect of a product with marketing authorisation, where the applicant is seeking authorisation for a product 'essentially similar' to a product holding a marketing authorisation for ten years (as per the United Kingdom and pursuant to art 10(i)(a)(iii) of the Directive).
In seeking marketing authorisation for Product C, the generic companies relied on data submitted in relation to Product A and Product B.
You hear a lot about people making a lot of money working some MLM opportunity but the only problem with these are that you need to make an investment and you have to know a lot of people. I have a guaranteed income each month that covers my rent but I'm at home all the time and not earning any additional money. When my wife and i first arrived in Brunswick we applied at a lot of local businesses b
In seeking marketing authorisation for Product C, the generic companies relied on data submitted in relation to Product A and Product B.
You can ready yourself for IT emergencies by having checklists, online resources, telephone support lines and tool kits on-hand at all times.When IT emergencies strike, start by comparing your abilities to the client's basic needs. What kind of hardware, operating system and applications are involved, and what aspects of the business is the problem affecting? If you don't weigh the situati
In seeking marketing authorisation for Product C, the generic companies relied on data submitted in relation to Product A and Product B. However, although Product A and Product B contained the same active ingredient, they were not 'essentially similar' within the meaning of the Directive. This meant that they differed in respect of their posology (the schedule of dosage). The defendant accepted that the generic companies did not have to provide any further data but the claimant argued that such an approach was unlawful and in breach of the Directive. The claimant made a reference to the European Court of Justice ("Court of Justice").
The claimant contended that the issue was as yet unresolved by the rules laid down in previous decisions of the ECJ. In particular, it was argued, that there had been no cases where a difference in posology had been the subject of a decision.
The application was dismissed. The ECJ held that:
The principles laid down by the ECJ in earlier decisions were clearly applicable in this case and there was no uncertainty;
Although it was true that a change in posology had not previously been the subject of a decision, it was for the ECJ to interpret the EC Treaty and the relevant principles by which it was to be interpreted, and for the domestic court to apply those principles to the particular
HTTP = HTML link (for blogs, profiles,phorums):
<a href="http://www.diggitup.net/article/253140/diggitup-Marketing-Authorisation--Medicinal-Products.html">Marketing Authorisation - Medicinal Products</a>
BB link (for phorums):
[url=http://www.diggitup.net/article/253140/diggitup-Marketing-Authorisation--Medicinal-Products.html]Marketing Authorisation - Medicinal Products[/url]
Related Articles:
The Importance of Patience and Perseverance in Success Online
Bookmark it:
|